Suppr超能文献

肺黏膜相关淋巴组织淋巴瘤的临床特征和预后因素。

Clinical characteristics and prognostic factors of pulmonary MALT lymphoma.

机构信息

Service de Pneumologie et Réanimation, Centre de Compétence Maladies Rares Pulmonaires, Hôpital Tenon, Paris, France.

出版信息

Eur Respir J. 2009 Dec;34(6):1408-16. doi: 10.1183/09031936.00039309. Epub 2009 Jun 18.

Abstract

Mucosa-associated lymphoid tissue-derived (MALT) lymphoma, a low grade B-cell extranodal lymphoma, is the most frequent subset of primary pulmonary lymphoma. Our objective was to evaluate the initial extent of disease and to analyse the characteristics and long-term outcome of these patients. All chest and pathological departments of teaching hospitals in Paris were contacted in order to identify patients with a histological diagnosis of primary pulmonary lymphoma of the MALT subtype. 63 cases were identified. The median age was 60 yrs. 36% of cases had no symptoms at diagnosis. 46% of patients had at least one extrapulmonary location of lymphoma. The estimated 5- and 10-yr overall survival rates were 90% and 72%, respectively. Only two of the nine observed deaths were related to lymphoma. Age and performance status were the only two adverse prognostic factors for survival. Extrapulmonary location of lymphoma was not a prognostic factor for overall survival or for progression-free survival. Treatment with cyclophosphamide or anthracycline was associated with shorter progression-free survival, when compared with chlorambucil. The survival data confirm the indolent nature of pulmonary MALT lymphoma. Better progression-free survival was observed with chlorambucil when compared with cyclophosphamide or anthracycline.

摘要

黏膜相关淋巴组织源性(MALT)淋巴瘤,一种低级别的 B 细胞结外淋巴瘤,是原发性肺淋巴瘤中最常见的亚型。我们的目的是评估疾病的初始范围,并分析这些患者的特征和长期预后。联系了巴黎所有教学医院的胸部和病理科,以确定组织学诊断为 MALT 型原发性肺淋巴瘤的患者。共确定了 63 例病例。中位年龄为 60 岁。36%的病例在诊断时无症状。46%的患者至少有一个结外淋巴瘤部位。估计 5 年和 10 年总生存率分别为 90%和 72%。9 例观察到的死亡中仅有 2 例与淋巴瘤有关。年龄和体能状态是生存的唯一两个不良预后因素。结外淋巴瘤部位不是总生存或无进展生存的预后因素。与苯丁酸氮芥相比,环磷酰胺或蒽环类药物治疗与无进展生存时间缩短相关。生存数据证实了肺 MALT 淋巴瘤的惰性性质。与环磷酰胺或蒽环类药物相比,苯丁酸氮芥观察到更好的无进展生存。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验